A study to investigate the use of benralizumab in patients with bullous pemphigoid

Phase 1

Conditions: Bullous Pemphigoid
MedDRA version: 21.1Level: LLTClassification code 10006567Term: Bullous pemphigoidSystem Organ Class: 100000004858
Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

Registration Number: EUCTR2020-000287-32-DE

Lead Sponsor: AstraZeneca AB

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 120

Inclusion Criteria

1. Adult participants = 18 years of age
2. Participants must have clinical features of BP (eg, urticarial or eczematous or erythematous plaques, bullae, pruritus) at the screening visit and confirmed diagnosis with histology, direct immunofluorescence, and serology at randomization. Required for inclusion:
(a) Histology.
(b) Positive direct immunofluorescence (from skin biopsy) (IgG and/or C3 at the
basement membrane zone).
(c) AND at least one of the following serologic assessments positive (all assessed from
participant’s blood sample):
(i) indirect immunofluorescence (IgG on the roof of salt- split skin).
(ii) positive serology on ELISA for BPAG1 (230-kd).
(iii) positive serology on ELISA for BPAG2 (180-kd).
3. BPDAI activity score = 24 at the screening and randomization visits.
4. Candidate for systemic corticosteroid therapy.
5. Able to complete PRO assessments on a tablet and on a handheld device. Some participants may be exempted from completing home PROs on the
handheld device upon agreement with the AstraZeneca physician (eg, if the patient has a medical condition such as BP lesions of the fingers/hand, a neurologic condition affecting fingers/hand, or severe visual impairment).
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 12
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 108

Exclusion Criteria

1. Forms of BP other than classic, predominantly cutaneous BP: eg,
mucous membrane BP, epidermolysis bullosa acquisita, Brunsting-Perry
BP, p200 BP, p105 BP, BP with concomitant pemphigus vulgaris, and
drug-induced BP.
2. Comorbid disease that in the Investigator's judgement might interfere
with the evaluation of the IP or safety of the participant. This includes
any disorder that in the opinion of the Investigator is not stable (eg,
cardiovascular, gastrointestinal, hepatic, renal, neurological,
musculoskeletal, infectious, endocrine, metabolic, hematological,
psychiatric, or major physical impairment).
3. Current or history of malignancy within 5 years before the screening
visit with the following exceptions:
(a) Participants treated for in situ carcinoma of the cervix who have
completed curative therapy and are in remission for at least 12 months
prior to signing the informed consent and
(b) Participants with superficial basal cell or squamous skin cancer.
(c) Participants who have had other malignancies are eligible provided
that the participant is in remission and curative therapy was completed
at least 5 years prior to the date informed consent was obtained.
4. History of anaphylaxis to any biologic therapy or vaccine.
5. A helminth parasitic infection diagnosed within 24 weeks prior to the
date informed consent is obtained that has not been treated with, or has
failed to respond to standard of care therapy.
6. Any clinically significant abnormal findings in physical examination,
vital signs, electrocardiogram (ECG), hematology, or clinical chemistry
during screening, which in the opinion of the Investigator, may put the
participant at risk because of his/her participation in the study or may
influence the results of the study.
7. Current active liver disease.
(a) Chronic stable hepatitis B and C (including positive testing for
hepatitis B surface antigen or hepatitis C antibody), or other stable
chronic liver disease are acceptable if participant otherwise meets
eligibility criteria. Stable chronic liver disease should generally be
defined by the absence of ascites, encephalopathy, coagulopathy,
hypoalbuminemia, esophageal or gastric varices, or persistent jaundice,
or cirrhosis.
(b) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
level = 3 times the upper limit of normal, confirmed by repeated testing
during screening period. Transient increase of AST/ALT level that
resolves by the time of randomization is acceptable if in the
Investigator's opinion the participant does not have an active liver
disease and meets other eligibility criteria.
8. A history of known immunodeficiency disorder including a positive
human immunodeficiency virus (HIV) test.
9. Use of immunosuppressive medication, including, but not limited to:
methotrexate, cyclosporine, azathioprine within 4 weeks or 5 half-lives
prior to the date informed consent is obtained, whichever is longer.
10. Receipt of immunoglobulin or blood products within 30 days prior to
the date informed consent is obtained.
11. Receipt of any marketed or investigational biologic within 4 months
or 5 half-lives prior to the date informed consent is obtained, whichever
is longer. Participants on stable therapy for at least 3 months before
randomization who intend to stay on treatment throughout the study
with marketed biologics that are not likely to interfere with the
assessment of safety and/or efficacy of benralizumab (eg, for the
treatment of osteoporosis, migraine,

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To compare the clinical efficacy of benralizumab with placebo in participants with symptomatic BP;Secondary Objective: 1. To compare the effect of benralizumab with placebo on supportive measures of clinical efficacy in participants with symptomatic BP up to Week 36.<br>2. To compare the effect of benralizumab with placebo on clinical efficacy in participants with symptomatic BP up to Week 16.<br>3. To estimate the PK and immunogenicity of benralizumab in participants with BP.<br>4. To compare the safety and tolerability of benralizumab with placebo in participants with symptomatic BP.;Primary end point(s): A binary response, whereby a responder is defined as a participant who is in complete<br>remission while off OCS for = 2 months at Week 36.;Timepoint(s) of evaluation of this end point: at Week 36

Secondary Outcome Measures

Name	Time	Method
Secondary end point(s): Key secondary : <br>• Proportion of participants who remain relapse-free up to Week 36.<br>• Cumulative OCS exposure (mg/kg) from baseline to Week 36.<br>• Change from baseline in BPDAI activity score at Week 36.<br>• Change from baseline in BPDAI-Pruritus score at Week 36.<br>• Cumulative OCS exposure (mg/kg) from baseline to Week 16.;Timepoint(s) of evaluation of this end point: various time points as per protocol

Related Trials